



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT TRANSMITTAL FORM

GP 2857
#7

Applicant(s): John R. Desjarlais

Serial No.: 10/071,859

Filed: February 6, 2002

For: APPARATUS AND METHOD FOR DESIGNING PROTEINS AND PROTEIN
LIBRARIES

Examiner: Not Yet Assigned

Art Unit: 2857

Attorney Docket: 823.0093USQ

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Dear Sir:

Transmitted herewith is:

1. Supplemental Information Disclosure Statement;
2. PTO Form 1449 with copies of patents;
3. Transmittal letter in duplicate; and
4. Postcard.

Please charge any additional fees or credit any such fees, if necessary to Deposit Account No. 01-0467 in the name of Ohlandt, Greeley, Ruggiero & Perle. A duplicate copy of this sheet is attached.

Respectfully submitted,

Date: December 9, 2002

Paul D. Greeley, Esq.
Reg. No. 31,019
Ohlandt, Greeley, Ruggiero & Perle, L.L.P.
One Landmark Square, 10th Floor
Stamford, Connecticut 06901-2682
(203) 327-4500

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE U.S. POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON DECEMBER 9, 2002.

Jeffrey J. Scepanski
NAME

SIGNATURE

12/09/02
DATE

RECEIVED
DEC 18 2002
TECHNOLOGY CENTER 2800

RECEIVED
DEC 24 2002
TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): John R. Desjarlais

Serial No.: 10/071,859

Filed: February 6, 2002

For: APPARATUS AND METHOD FOR DESIGNING PROTEINS AND PROTEIN LIBRARIES

Examiner: Not Yet Assigned

Art Unit: 2857

Attorney Docket: 823.0093USQ

RECEIVED
DEC 18 2002
TECHNOLOGY CENTER 2800

RECEIVED

DEC 24 2002

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with applicant's duty of disclosure under 37 C.F.R. §1.56, please find attached hereto form PTO-1449 listing information which may be material to the patentability of this application. This Information Disclosure Statement is being filed:

___ Within three (3) months of the filing date of the national application;

___ Within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application;

XXX Before the mailing date of a first Office Action on the merits;

___ After the filing date or date of first Office Action, but before the mailing date of a final action under 37 C.F.R. §1.113, provided that this occurs prior to the issuance of a Notice of Allowance and provided that this I.D.S. is accompanied by either a certification as specified in 37 C.F.R. §1.97(e) or the fee set forth in 37 C.F.R. §1.17(p);


— After the filing date or date of first Office Action, but before the mailing date of a Notice of Allowance under 37 C.F.R. §1.311, provided that this occurs prior to the final action and provided that this I.D.S. is accompanied by either a certification as specified in 37 C.F.R. §1.97(e) or the fee set forth in 37 C.F.R. §1.17(p);

— After the mailing date of a final action under 37 C.F.R. §1.113, provided that this occurs prior to the issuance of a Notice of Allowance and provided that this I.D.S. is accompanied by either a certification as specified in 37 C.F.R. §1.97(e), a petition requesting consideration of the I.D.S., and the petition fee set forth in 37 C.F.R. §1.17(i)(1); and

— After the mailing date of a Notice of Allowance under 37 C.F.R. §1.311, provided that this occurs prior to the issuance of a final action and provided that this I.D.S. is accompanied by either a certification as specified in 37 C.F.R. §1.97(e), a petition requesting consideration of the I.D.S., and the petition fee set forth in 37 C.F.R. §1.17(l)(1).


It should be understood that attention has been called to the references that have been deemed to be pertinent to the claimed present invention. In concluding what was pertinent, the criteria employed was considered most appropriate in light of the invention shown in the present application. However, the Examiner or others may deem some other criteria to be just as appropriate or more appropriate. Therefore, the Examiner is respectfully urged to review the listed references and to make the usual careful independent search for other prior art that may be pertinent.

Respectfully submitted,



Date: December 9, 2002

Paul D. Greeley
Reg. No. 31,019
Ohlandt, Greeley, Ruggiero & Perle, L.L.P.
One Landmark Square, 10th Floor
Stamford, CT 06901-2682
(203) 327-4500

Sheet 1 of 1.

FORM PTO-1449			Docket Number (Optional) 823.0093USQ		Application Number 10/071,859		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)			Applicant John R. Desjarlais				
			Filing Date February 6, 2002		Group Art Unit 2857		
U. S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES NO	
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)							
	Kiedrowski et al. "Parabolic growth of a self-replicating Hexadeoxynucleotide bearing a 3'-5'-Phosphoamidate Linkage." Angew. Chem. Int. Ed. Engl. 30 (1991) No. 4, 423-426.						
	Meier et al. "Peptide nucleic acids (PNAs)-Unusual properties of nonionic oligonucleotide analogues." Angew. Chem. Int. Ed. Engl. 31 (1992) No. 8, 1008-1010.						
	Pauwels et al. "Biological activity of new 2-5 A analogues." Chemica Scripta 1986, 26, 141-145.						
	Vasquez. "An evaluation of discrete and continuum search techniques for conformational analysis of side chains in Proteins." Biopolymers. Vol. 36, 53-70 (1995).						
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							